PPARA and metabolic dysfunction-associated steatohepatitis: The ability of PPARα to stimulate fatty acid oxidation and suppress hepatic inflammation has led to the exploration of PPARα agonists as a therapeutic option for nonalcohol fatty liver disease and specifically nonalcoholic steatohepatitis (NASH).